Erratum to: ‘Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis’ [J Hepatol (2024) 80:268-281, (S0168827823052352), (10.1016/j.jhep.2023.10.035)] (2025) Ghallab A, González D, Strängberg E, Hofmann U, Myllys M, Hassan R, Hobloss Z, et al. Journal article, Erratum Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis (2024) Ghallab A, González D, Strängberg E, Hofmann U, Myllys M, Hassan R, Hobloss Z, et al. Journal article MiR-122, the regulator of the immune privileged liver (2022) Gefen M, Layani S, Klahr E, Hindi M, Rosenberg N, Abramovitch R, Nachmansson N, et al. Conference contribution Chronic pruritus represents a major burden in non-cholestatic hepatobiliary disorders (2022) Düll M, Karlen V, Vetter M, Dietrich P, Kupfer J, Neurath M, Kremer A Conference contribution A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis (2022) Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DE, Dörffel Y, Gordon SC, et al. Journal article Hepatobiliary malignancy surveillance strategies in primary sclerosing cholangitis associate with reduced mortality (2021) Bergquist AM, Weismueller T, Levy C, Rupp C, Joshi D, Nayagam J, Montano-Loza AJ, et al. Conference contribution Implementation of a national registry for patients with primary biliary cholangitis (PBC): The German PBC cohort (2021) Wiegand J, Stein K, Guenther R, Naumann U, Zimny S, Reuken P, Boettler T, et al. Conference contribution Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy (2021) Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer A, et al. Journal article F-actin dynamics regulates mammalian organ growth and cell fate maintenance (2019) Pocaterra A, Santinon G, Romani P, Brian I, Dimitracopoulos A, Ghisleni A, Carnicer-Lombarte A, et al. Journal article Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019) Dalekos G, Invernizzi P, Nevens F, Hans VV, Zigmond E, Andrade RJ, Ben Ari Z, et al. Conference contribution